EGFR and colorectal carcinoma: To date, only a retrospective observational study evaluated aflibercept-FOLFIRI as second-line treatment in a homogeneus series of 120 WT RAS CRC patients who had received a first-line standard CT plus anti-EGFR (epidermal growth factor receptor) moAb, describing an ORR of 33%, a median PFS of 6.9 months (95% CI: 6.1–7.8) and a median OS of 14.5 months (95% CI: 9.7–19.3) [27].